Kaufman v. I-Stat Corp.

754 A.2d 1188, 165 N.J. 94, 2000 N.J. LEXIS 993
CourtSupreme Court of New Jersey
DecidedJuly 27, 2000
StatusPublished
Cited by117 cases

This text of 754 A.2d 1188 (Kaufman v. I-Stat Corp.) is published on Counsel Stack Legal Research, covering Supreme Court of New Jersey primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Kaufman v. I-Stat Corp., 754 A.2d 1188, 165 N.J. 94, 2000 N.J. LEXIS 993 (N.J. 2000).

Opinions

The opinion of the Court was delivered by

LaVECCHIA, J.

This appeal presents the question whether a class of plaintiffs in a common-law action for fraud can prove the element of reliance through the presumption of a fraud on the market. The theory of fraud on the market, as described by the United States Supreme Court in Basic Inc. v. Levinson, 485 U.S. 224, 108 S.Ct. 978, 99 L.Ed.2d 194 (1988), allows plaintiffs to bring class actions under federal securities-fraud law by excusing those plaintiffs from the burden of proving individual reliance. Instead, plaintiffs may establish the reliance element of their claims by showing that they purchased securities in the secondary markets at attractive prices that had been artificially affected by an issuer’s misrepresentations and omissions.

Plaintiff Susan Kaufman held shares of defendant i-Stat Corporation (“i-Stat”) over a period during which i-Stat allegedly misrepresented certain financial matters and the misrepresentations were discovered and publicized. The misrepresentations were never made to Kaufman by i-Stat or any intermediary. Kaufman relied on the price of the stock in her decisions, and now contends that, because i-Stat’s misrepresentations were reflected in the share price, she can make out claims for common-law fraud and negligent misrepresentation on the basis of the share price alone.

Even though the theory of fraud on the market has a place in the securities law of this nation, it is a stranger to New Jersey’s securities laws. It is also not consistent with the current requirements for a common-law action for fraud in New Jersey. Use of the fraud-on-the-market theory is not the equivalent of proof of indirect reliance that is required minimally in a common-law fraud action. Because we discern no compelling reason to deviate from our current standard of proof for the reliance element in a common-law fraud action, and because we, like many commenta[98]*98tors, cast a jaundiced eye on the worth of the fraud-on-the-market theory, we decline to expand our common law to permit its use. Accordingly, we reverse the judgment of the Appellate Division and reinstate the trial court’s dismissal of plaintiffs fraud claim.

I.

This matter comes before the Court as a result of the Law Division’s grant of summary judgment for the defendants. Accordingly, we give the plaintiff the benefit of every positive inference to be drawn from the facts as she has pled them. See Brill v. Guardian Life Ins. Co. of Am., 142 N.J. 520, 523, 666 A.2d 146 (1995). In that light, we thus consider the facts.

i-Stat is a public New Jersey corporation that manufactures and markets diagnostic blood-analysis equipment designed to assist medical professionals at the point of patient care. Specifically, the company makes a hand-held blood analyzer and cartridges to test individual patients. The corporation’s stock is traded on the NASDAQ National Market System. On October 31, 1995, during the events at issue in this action, i-Stat had 11,083,421 shares of common stock issued and outstanding.

On May 9, 1995, i-Stat announced its financial results for the first fiscal quarter of 1995, ending March 31. The company reported net sales of $3,359,000, as compared to reported net sales of $1,651,000 for the same period in the previous year. The company reported a net loss of $6,531,000 ($0.59 per share) for the first quarter as compared with a net loss of $6,056,000 ($0.55 per share) for the same period in the prior year. Kaufman alleges that, to produce the improved sales figures, i-Stat1 misrepresented acceptance of the company’s products to the public by “re[99]*99porting] sales that were not, in fact, true sales, but were, instead, loans on a trial basis.” For example, i-Stat allegedly reported “sales” to certain hospitals without disclosing that the “sales” were induced by “charitable donations” from interested third parties to the purchasing hospitals. These sales practices resulted in an exaggerated representation of the company’s sales and degree of market acceptance of its products.

On May 22, 1995, Susan Kaufman purchased one hundred shares of i-Stat common stock at 21 %, a total investment of $2175. Meanwhile, on that date, Forbes magazine reported that a medical investment newsletter believed i-Stat was experiencing difficulties and that its products were not economical. On June 21, 1995, an article in The Financial Post, a Canadian financial publication, reported “the expected profitability and growth of the Company,” citing an interview with defendant Imants Lauks. On September 21, 1995, i-Stat reached its all-time high, trading at 43 %.

The bubble began to burst on January 28, 1996. On that date, The New York Times reported that Daniel R. Frank, manager of the Fidelity Advisor Strategic Opportunities Fund, whose successor is still the largest institutional holder of i-Stat, had made charitable contributions to hospitals to enable them to obtain i-Stat’s diagnostic equipment.

Then, on March 19,1996, The Wall Street Journal reported that the Securities and Exchange Commission (“SEC”) was investigating i-Stat’s business. The article revealed that some of i-Stat’s “sales” had been loans of the products to hospitals on a trial basis rather than actual sales. i-Stat responded with a press release confirming the SEC’s investigation and inquiry into its sales procedures. On that same day, i-Stat’s shares, which had been declining, tumbled 2$ to 28 % Two million shares of i-Stat, nearly one sixth of the shares outstanding on that date, traded on March 19.

On May 20, 1996, Kaufman sold 50 shares at 20 14. On June 19, she filed suit as putative class representative on behalf of all purchasers of i-Stat common stock between May 9, 1995, and [100]*100March 19, 1996, excluding the officers and directors of the company. Kaufman alleged common-law fraud and negligent misrepresentation, contending that i-Stat’s deliberately false and misleading statements regarding its financial status and deceptive sales practices inflated the stock price during the class period. Kaufman also alleged that i-Stat’s officers and directors illegally received over $2.9 million from insider trading during the class period.

i-Stat filed an answer alleging various affirmative defenses. Both parties stipulated to the following: (1) Kaufman did not “actually or directly receive or rely on any communication containing any misrepresentation ... nor ... actually receive or rely on any communication which omitted material facts[;]” (2) Kaufman purchased her stock through a brokerage firm and did not directly receive or rely on any communication from the brokerage firm concerning the i-Stat purchase; and (3) Kaufman “relied exclusively on the integrity of the market price of i-Stat stock at the time of her purchase.” Therefore, Kaufman’s satisfaction of the reliance element of the common-law fraud and negligent-misrepresentation claims depends entirely on the fraud-on-the-market theory.

i-Stat moved for summary judgment on the ground that Kaufman failed to state a cause of action in fraud or in negligent misrepresentation because she could not satisfy the actual reliance requirement in each. The trial court granted the motion, dismissing Kaufman’s claims with prejudice. Although the court agreed with the fraud-on-the-market theory Justice Blackmun espoused in Basic, supra,

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
754 A.2d 1188, 165 N.J. 94, 2000 N.J. LEXIS 993, Counsel Stack Legal Research, https://law.counselstack.com/opinion/kaufman-v-i-stat-corp-nj-2000.